Print

HVTN 108

A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DNA, and of MF59?- or AS01B-Adjuvanted Clade C Env Protein in Various Combinations, in Healthy, HIV-Uninfected Adult Participants

Trial Details:

I/II Ongoing
National Institute of Allergy and Infectious Diseases (NIAID)
DNA-HIV-PT123,Bivalent Subtype C gp120/AS01B ,Bivalent Subtype C gp120/MF59 DNA clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef; Protein Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env
DNA-HIV-PT123 DNA
Bivalent Subtype C gp120/AS01B Protein
Bivalent Subtype C gp120/MF59 Protein
MF59
South Africa, USA 334
NCT02915016
https://www.clinicaltrials.gov/ct2/show/NCT02915016